InsidersTradesSigma
Lifevantage Corp Stock: price and management transactions · United States · SEC (Form 4)
Follow the Lifevantage Corp share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Lifevantage Corp has logged 199 public disclosures. Market capitalisation: €78.5m. The latest transaction was disclosed on 6 July 2026 (Retenue fiscale). Among the most active insiders: Fife Steven R. All data is accessible without an account.
199
Insider Decl.
0
Thresholds
€276,600
21 ops.
Buy Volume
€697,037
10 ops.
Sell Volume
34Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 931 of 25,821 companies
81.0
score / 100
Value88
Quality74
FCF yld13%
Earn yld12%
EV/EBITDA5.9x
ROE17%
Gross mgn80%
Net mgn4.3%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 6 July 2026
Declarations199 total
10,000 shares@ US$8.54590.062% mcap7.2% of flowCommon StockSEC:0001193125-26-259533:0
805 shares@ US$6.53990.0028% mcap2.9% of flowCommon StockSEC:0001628280-25-057657:0
Ideal exit: 11 Sept 2026 (T+270)
805 shares@ US$6.53992.9% of flowCommon StockSEC:0001628280-25-057657
Ideal exit: 11 Sept 2026 (T+270)
13,531 shares@ US$7.7643.7% of flowCommon StockSEC:0001628280-25-051224:0
13,531 shares@ US$7.769.6% of flowCommon StockSEC:0001628280-25-051221:0
1,000 shares@ US$7.330.7% of flowCommon StockSEC:0001628280-25-051221:1
35,000 shares@ US$6.921522.1% of flowCommon StockSEC:0001628280-25-051221:2
450 shares@ US$10.84990.0025% mcap2.7% of flowCommon StockSEC:0001698767-25-000003:0
Ideal exit: 13 Jun 2026 (T+270)
450 shares@ US$10.84992.7% of flowCommon StockSEC:0001698767-25-000003
Ideal exit: 13 Jun 2026 (T+270)
601 shares@ US$12.251.5% of flowCommon StockSEC:0000849146-25-000043:0
Ideal exit: 3 Feb 2026 (T+270)
3,659 shares@ US$12.1447.1% of flowCommon StockSEC:0000849146-25-000035:0
3,000 shares0Common StockSEC:0000849146-25-000031:0
3,668 shares0Common StockSEC:0000849146-25-000029:0
2,667 shares0Common StockSEC:0000849146-25-000032:0
21,089 shares@ US$15.7922.9% of flowCommon StockSEC:0000849146-25-000033:0
2,890 shares@ US$18.5647.5% of flowCommon StockSEC:0000849146-25-000023:0
4,450 shares@ US$20.0218.6% of flowCommon StockSEC:0000849146-25-000020:0
5,850 shares@ US$19.5411.7% of flowCommon StockSEC:0000849146-25-000019:0
8,000 shares@ US$20.152727.8% of flowCommon StockSEC:0000849146-25-000021:0
2,668 shares0Common StockSEC:0000849146-25-000006:0
3,667 shares0Common StockSEC:0000849146-25-000009:0
22,982 shares@ US$17.5328.8% of flowCommon StockSEC:0000849146-25-000010:0
25 of 199 declarations
About Lifevantage Corp
LifeVantage Corp (NASDAQ: LFVN) is a U.S.-based health and wellness company headquartered in Lehi, Utah, United States. Founded in 2003, the company is best known for its focus on nutrigenomics, a field that examines how nutrition and naturally occurring compounds may influence gene expression and support wellness-related biological processes. For French-speaking investors, LifeVantage fits best as a niche player in preventive health and dietary supplements, with a direct-selling business model that relies heavily on an independent consultant network. The company’s core business centers on health and nutrition products built around the idea of “activation” at the cellular level. Its portfolio includes Protandim-branded supplements, weight-management and metabolic wellness offerings, and broader health products. In 2025 and 2026, LifeVantage highlighted its MindBody GLP-1 System™, a product platform tied to current consumer interest in metabolism and weight management. The company also strengthened its portfolio through the integration of LoveBiome, which expanded LifeVantage into adjacent wellness categories and added another growth lever to the business. From a competitive standpoint, LifeVantage operates in a highly fragmented market where success depends on brand differentiation, scientific credibility, distribution efficiency, and the ability to refresh the product lineup. The company emphasizes science-backed positioning and nutrigenomics-based messaging, but it faces intense competition from supplement companies, functional nutrition brands, and mass-market wellness players. Its international footprint is an important strategic advantage: beyond its U.S. base, LifeVantage has continued expanding the MB System internationally, including into Asia-Pacific, Europe, and other overseas markets. Recent highlights include the international rollout of the MindBody GLP-1 System, the integration of LoveBiome, and continued product and commercial events designed to energize its consultant base. LifeVantage has also communicated fiscal 2026 financial guidance and continues to emphasize product innovation, global business events, and network activation as part of its growth strategy. For investors looking at a small-cap U.S.-listed wellness company on the NASDAQ, LifeVantage offers exposure to a science-oriented direct-selling model with growth potential that depends on product execution, international expansion, and the strength of its consultant-driven sales engine.
